Overview

Useful For
Monitoring coagulation factor replacement therapy of selected extended half-life coagulation factor replacements

Aiding in the diagnosis of hemophilia B using a 2-stage assay, especially when a 1-stage assay was normal

Testing Algorithm
This assay is indicated in situations where there is a clinical suspicion of hemophilia B diagnosis, when the 1-stage assay is normal. However, this assay is also recommended for accurate classification of hemophilia B.

See Hemophilia Testing Algorithm in Special Instructions

Special Instructions

Coagulation Guidelines for Specimen Handling and Processing
Hemophilia Testing Algorithm

Method Name
Chromogenic

NY State Available
Yes

Specimen

Specimen Type
Plasma Na Cit

Advisory Information
Coagulation testing is highly complex, often requiring the performance of multiple assays and correlation with clinical information. For that reason, ALBLD / Bleeding Diathesis Profile, Limited, Plasma is recommended.

Necessary Information
If a priority specimen, mark request form, give reason, and request a call-back.

Specimen Required
See Coagulation Guidelines for Specimen Handling and Processing in Special Instructions.

Specimen Type: Platelet-poor plasma

Collection Container/Tube: Light-blue top (3.2% sodium citrate)

Submission Container/Tube: Polypropylene vial

Specimen Volume: 1 mL

Collection Instructions:
1. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
2. Aliquot plasma a separate plastic vial leaving 0.25 mL in the bottom of centrifuged vial.

3. Freeze plasma immediately (no longer than 4 hours after collection) at -20 degrees C or, ideally at < or =-40 degrees C.

**Additional Information:**

1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.

2. Each coagulation assay requested should have its own vial.

**Forms**

If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.

**Specimen Minimum Volume**

0.5 mL

**Reject Due To**

<table>
<thead>
<tr>
<th>Gross hemolysis</th>
<th>OK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross lipemia</td>
<td>OK</td>
</tr>
<tr>
<td>Gross icterus</td>
<td>OK</td>
</tr>
</tbody>
</table>

**Specimen Stability Information**

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
<th>Special Container</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma Na Cit</td>
<td>Frozen</td>
<td>14 days</td>
<td></td>
</tr>
</tbody>
</table>

**Clinical and Interpretive**

**Clinical Information**

Factor IX (FIX) is a vitamin K-dependent serine protease synthesized in the liver and participates in the intrinsic coagulation pathway. Its biological half-life is 18 to 24 hours.

Congenital FIX deficiency is inherited as an X-linked recessive bleeding disorder (hemophilia B). Severe deficiency (<1%) characterized by hemarthroses, deep tissue bleeding, excessive bleeding with trauma, and ecchymoses.

Typically, these patients are tested using a 1-stage clotting assay. However, new treatment options using long-acting glycoPEGylated replacement products are being approved for clinical use. Pharmacokinetic studies for these products indicate ideal monitoring of patients should be performed by the 2-stage chromogenic assay.

**Reference Values**

65-140%

Chromogenic Factor IX activity generally correlates with the one-stage FIX activity. In full term/premature neonates, infants, children, and adolescents the one-stage FIX activity* is similar to adults. However, no similar data for chromogenic FIX activity are available. (Appel JTH 2012; 10:2254)
Interpretation
Factor IX deficiency may be acquired (e.g., vitamin K deficiency, warfarin anticoagulation effect, liver disease, or a consumptive coagulopathy) or congenital (hemophilia B).

Optimal laboratory monitoring of selected extended half-life factor IX replacement therapy (e.g., glycoPEGylated factor FIX) may be achieved with the chromogenic factor IX assay. Elevated factor IX levels may be associated with acute or chronic inflammation, excess factor IX replacement therapy, or as a result of a rare genetic variant, factor IX Padua.

Cautions
Excess heparin and dilution contamination due to improper specimen collection through an intravenous access device may result in artifactually decreased results.

The 1-stage and chromogenic factor IX (FIX) assay results should correlate in the normal population, but may be discordant in the hemophilia population and when measuring factor replacement, especially with PEGylated recombinant FIX products.

Clinical Reference

Performance
Method Description
The chromogenic factor IX assay is performed on the Instrumentation Laboratory ACL TOP 700 using the Rossix ROX Factor IX kit. In this 2-stage assay, patient plasma is diluted and combined with reagents containing factors VIII, X, V, Xla, and II, fibrin inhibitor, calcium chloride, and phospholipids. The factor IX in the patient's plasma is activated to IXa, which then aids in the activation of factor X to factor Xa. After a specified incubation period, chromogenic substrate is added at which time, the factor Xa, present from the previous step, hydrolyzes the substrate into peptide and pNA. The color produced by the release of pNA is measured photometrically at 405 nm and is proportional to the factor IX in the sample. (Package insert: ROX FACTOR IX kit. Rossix AB, Molndal, Sweden, Rev 04/2014)

PDF Report
No
Test Definition: CH9
Chromogenic FIX, P

Day(s) and Time(s) Test Performed
Monday through Friday

Analytic Time
1 day

Maximum Laboratory Time
3 days

Specimen Retention Time
7 days

Performing Laboratory Location
Rochester

Fees and Codes

Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information
85130

LOINC® Information

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CH9</td>
<td>Chromogenic FIX, P</td>
<td>88449-4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CH9</td>
<td>Chromogenic FIX, P</td>
<td>88449-4</td>
</tr>
</tbody>
</table>